Skip to main content
OpenTrials
Completed

NCT Number: NCT00772811

Using Fludarabine and Melphalan Conditioning Regimen for CLL,Lymphoma,Multiple Myeloma

Allogeneic Non-Myeloablative Stem Cell Transplantation Using Fludarabine and Melphalan Conditioning Regimen for Chronic Lymphocytic Leukemia, Lymphoma, and Multiple Myeloma

Completed

Looking for future studies?

Notify Me

Key information

About this study

Treatment plan

  • Conditioning chemotherapy before infusion of allogeneic stem cells will include fludarabine 30 mg/m2/day for 5 consecutive days (days -6 to -2) and melphalan 100 mg/m2 at day -2.
  • Fludarabine and Melphalan will be infused intravenously over 30 minutes in D5W 100 mL.
  • Melphalan will be administered following the completion of Fludarabine infusion at day -2.
  • In case of unrelated donor HCT, thymoglobuline 3 mg/kg in N/S 500 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500 mL (less than 2 mg/mL) IV qd on days -4, -3 and -2. Infuse over 4 hrs. Premedicate with Avil 45.5 mg IVP and Tylenol 600 mg po. Methylprednisolone 2 mg/kg in D5W 100 ml will be given IV over 30 minutes before thymoglobulin (or lymphoglobuline) on days -4 to -2.
  • Before the administration of melphalan, prehydration will be done intravenously with 0.9% NS 1L over 3 hours.
  • 30 minutes before melphalan infusion, premedication with dexamethasone 10 mg and ativan 1 mg i.v. push will be given. Appropriate antiemetics such as ondansetron 8 mg i.v. push every 4-6 hours and ativan 1-2 mg i.v. push every 4-6 hours will be administered.
  • Hydration with 0.9% NS at 80 mL/hour will be administered for at least 7 days. Appropriate amount of KCl should be mixed.
  • GVHD prophylaxis will include cyclosporine A (CSA) and methotrexate.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients must be 15 years of age or older and 65 years of age or younger
  • Patients with CLL, lymphoma, or multiple myeloma will be included in this study
  • No prior anti-cancer treatment should be done within 30 days.
  • Informed consent should be given.
  • Patients should have an HLA-identical or single HLA-locus mismatched donor.
  • Karnofsky performance scale should be 50 or over (see Appendix I).

Exclusion criteria

  • Patients must not have a psychiatric disorder or mental deficiency severe as to make compliance with the stem cell transplant treatment unlike, and making informed consent impossible.
  • Patients with high serum creatinine level will be excluded.
  • Patients should have uncontrolled infection.
  • No major anticipated illness or organ failure incompatible with survival from stem cell transplant.
  • Serum bilirubin less than or equal to 4.0 mg/dL.

Treatment and study plan

Flu-Mel

Drug
  • Fludarabine and Melphalan will be infused intravenously over 30 minutes in D5W 100 mL.
  • Melphalan will be administered following the completion of Fludarabine infusion at day -2.

Other names: Fludara-Alkaran

Primary outcomes

  1. To evaluate engraftment, chimerism, toxicity, incidence of acute graft-versus-host disease (GVHD), and day 100 treatment-related mortality (TRM)

    Time frame: 9years

    -To evaluate engraftment, chimerism, toxicity, incidence of acute graft-versus-host disease (GVHD), and day 100 treatment-related mortality (TRM) following allogeneic nonmyeloablative stem cell transplantation using fludarabine and melphalan conditioning regimen in patients with chronic lymphocytic leukemia (CLL), lymphoma, and multiple myeloma.

Secondary outcomes

  1. include tumor response, incidence of chronic GVHD, and immune reconstitution.

    Time frame: 9years

    -The secondary objectives include tumor response, incidence of chronic GVHD, and immune reconstitution.

Sponsors and collaborators

Lead sponsor

Cooperative Study Group A for Hematology

Network

Registry information

Official study title

Allogeneic Non-Myeloablative Stem Cell Transplantation Using Fludarabine and Melphalan Conditioning Regimen for Chronic Lymphocytic Leukemia, Lymphoma, and Multiple Myeloma

Acronym: Flu-Mel

Important dates

Study start
2001
Primary completion
2010
Study completion
2010
First posted
Oct 15, 2008
Registry last updated
Feb 17, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.